114 related articles for article (PubMed ID: 26019034)
21. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
[TBL] [Abstract][Full Text] [Related]
22. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.
Miailhes P; Gilbert C; Lacombe K; Arends JE; Puoti M; Rockstroh JK; Sogni P; Fontaine H; Rosenthal E; Winnock M; Loko MA; Wittkop L; Dabis F; Salmon D;
Liver Int; 2015 Sep; 35(9):2090-9. PubMed ID: 25650873
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
Foster GR; Pianko S; Brown A; Forton D; Nahass RG; George J; Barnes E; Brainard DM; Massetto B; Lin M; Han B; McHutchison JG; Subramanian GM; Cooper C; Agarwal K;
Gastroenterology; 2015 Nov; 149(6):1462-70. PubMed ID: 26248087
[TBL] [Abstract][Full Text] [Related]
24. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
25. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.
Cortesi PA; Ciaccio A; Rota M; Lim JK; De Salvia S; Okolicsanyi S; Vinci M; Belli LS; Mantovani LG; Strazzabosco M
J Viral Hepat; 2015 Feb; 22(2):175-83. PubMed ID: 25040391
[TBL] [Abstract][Full Text] [Related]
26. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.
El-Khayat HR; Fouad YM; Maher M; El-Amin H; Muhammed H
Gut; 2017 Nov; 66(11):2008-2012. PubMed ID: 27511197
[TBL] [Abstract][Full Text] [Related]
28. HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
Sarrazin C; Manns M; Calleja JL; Garcia-Samaniego J; Forns X; Kaste R; Bai X; Wu J; Stern JO
PLoS One; 2016; 11(12):e0168544. PubMed ID: 28030579
[TBL] [Abstract][Full Text] [Related]
29. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Roulot D; Thibault V; Laforest C; Fontaine H; Bronowicki JP; Asselah T; Bourlière M; Canva V; Leroy V; Loustaud-Ratti V; Ouzan D; Zoulim F; Schischmanoff O; Rousseau C; Renault A; Petrov-Sanchez V; Diallo A; Bellissant E; Serfaty L;
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):302-309. PubMed ID: 29271782
[TBL] [Abstract][Full Text] [Related]
31. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
Colombo M; Fernández I; Abdurakhmanov D; Ferreira PA; Strasser SI; Urbanek P; Moreno C; Streinu-Cercel A; Verheyen A; Iraqi W; DeMasi R; Hill A; Läuffer JM; Lonjon-Domanec I; Wedemeyer H
Gut; 2014 Jul; 63(7):1150-8. PubMed ID: 24201995
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
Zeuzem S; Asselah T; Angus P; Zarski JP; Larrey D; Müllhaupt B; Gane E; Schuchmann M; Lohse A; Pol S; Bronowicki JP; Roberts S; Arasteh K; Zoulim F; Heim M; Stern JO; Kukolj G; Nehmiz G; Haefner C; Boecher WO
Gastroenterology; 2011 Dec; 141(6):2047-55; quiz e14. PubMed ID: 21925126
[TBL] [Abstract][Full Text] [Related]
33. IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection.
Jiménez-Sousa MA; Berenguer J; Rallón N; Pineda-Tenor D; Aldamiz-Echevarria T; Soriano V; García-Álvarez M; Vazquez-Morón S; Restrepo C; Carrero A; Benito JM; Resino S
Liver Int; 2016 Sep; 36(9):1258-66. PubMed ID: 26836972
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus (HCV) genotype 1 NS5A resistance-associated variants are associated with advanced liver fibrosis independently of HCV-transmission clusters.
Parczewski M; Kordek J; Janczewska E; Pisula A; Łojewski W; Socha Ł; Wawrzynowicz-Syczewska M; Bociąga-Jasik M; Szymczak A; Cielniak I; Siwak E; Mularska E; Aksak-Wąs B; Urbańska A; Lübke N
Clin Microbiol Infect; 2019 Apr; 25(4):513.e1-513.e6. PubMed ID: 29981869
[TBL] [Abstract][Full Text] [Related]
35. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
Puigvehí M; De Cuenca B; Viu A; Diago M; Turnes J; Gea F; Pascasio JM; Lens S; Cabezas J; Badia E; Olveira A; Morillas RM; Torras X; Montoliu S; Cordero P; Castro JL; Salmerón J; Molina E; Sánchez-Ruano JJ; Moreno J; Antón MD; Moreno JM; De la Vega J; Calleja JL; Carrión JA
Liver Int; 2019 Jan; 39(1):90-97. PubMed ID: 30160363
[TBL] [Abstract][Full Text] [Related]
36. Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
El Raziky M; Gamil M; Ashour MK; Sameea EA; Doss W; Hamada Y; Van Dooren G; DeMasi R; Keim S; Lonjon-Domanec I; Hammad R; Hashim MS; Hassany M; Waked I
J Viral Hepat; 2017 Feb; 24(2):102-110. PubMed ID: 27790789
[TBL] [Abstract][Full Text] [Related]
37. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
[TBL] [Abstract][Full Text] [Related]
38. [Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].
Tural C; Planas R
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():19-25. PubMed ID: 24063899
[TBL] [Abstract][Full Text] [Related]
39. [Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
Crespo J; Berenguer M; Pérez F; Fernández I; González O; Bárcena R; Buti M; López J; Calleja JL;
Gastroenterol Hepatol; 2015 Nov; 38(9):517-24. PubMed ID: 25976446
[TBL] [Abstract][Full Text] [Related]
40. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]